Drug-eluting stents in patients with end-stage renal disease

Area of Science:

• Cardiology
• Nephrology
• Interventional Cardiology

Background:

• Advanced coronary artery disease (CAD) and acute cardiac events are leading causes of mortality in end-stage renal disease (ESRD) patients.
• ESRD patients are often excluded from clinical trials on coronary interventions, leading to a lack of evidence-based treatment guidelines for this high-risk group.
• The risk-benefit profile of cardiac interventions differs significantly in ESRD patients compared to those with normal renal function.

Purpose of the Study:

• To review the current literature on CAD prevalence and its impact on ESRD patients.
• To discuss the challenges in referring ESRD patients for coronary revascularization.
• To evaluate the potential role of drug-eluting stents (DES) in managing CAD in ESRD patients.

Main Methods:

• Literature review of studies on CAD, ESRD, and coronary revascularization strategies.
• Analysis of the impact of drug-eluting stents (DES) on target vessel revascularization.
• Discussion of clinical decision-making algorithms for percutaneous vs. surgical revascularization in ESRD patients.

Main Results:

• Drug-eluting stents (DES) have significantly reduced target vessel revascularization rates, influencing traditional revascularization algorithms.
• While DES utilization has increased, robust randomized clinical trial evidence for efficacy and safety in ESRD patients is lacking.
• Practicing cardiologists are increasingly adopting DES, particularly for high-risk populations like ESRD patients.

Conclusions:

• Coronary artery disease (CAD) poses a significant threat to patients with end-stage renal disease (ESRD).
• Drug-eluting stents (DES) represent a promising therapeutic option for CAD in ESRD patients, despite limited definitive clinical trial data.
• Further research and randomized trials are warranted to establish the definitive role and safety of DES in this vulnerable patient population.